Pacific Biosciences: Longer Reads, But Shorter Patience (Downgrade)
Source: SeekingAlpha
2025-12-18 11:20:17 ET
Although the shares of long-read sequencing specialist Pacific Biosciences of California, Inc. ( PACB ) (“PacBio”) have done better of late, rising more than 25% since my last "Buy" update in February and outperforming both Illumina ( ILMN ) and Oxford Nanopore ( ONTTF ) (ONT.L), this company is still a long way from being out of the woods, let alone on a stable and sustainable growth trajectory....
Read the full article on Seeking Alpha
For further details see:
Pacific Biosciences: Longer Reads, But Shorter Patience (Downgrade)
Pacific Biosciences of California Inc.
NASDAQ: PACB
PACB Trading
4.72% G/L:
$1.33 Last:
3,202,013 Volume:
$1.30 Open:
PACB Latest News
March 05, 2026 08:30:00 am
PacBio Announces the Appointment of Chris Gibson to the Board of Directors
February 24, 2026 09:05:00 am
PacBio and DNAstack Launch First Global Federated HiFi Whole Genome Dataset to Accelerate Rare Disease Research
February 18, 2026 04:05:00 pm
PacBio to Participate in the TD Cowen 46th Annual Health Care Conference
PACB Stock Data
$549,471,524
294,359,745
0.64%
78
N/A
Biotechnology & Life Sciences
Healthcare
US
Menlo Park
